EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Enbrel 25 mg powder and solvent for solution for injection
- Sustiva 50 mg, 100 mg and 200 mg Hard Capsules
- Sandostatin LAR
- Difflam Oral Rinse
- Teoptic 1% - Teoptic 2%
- Erythroped A 500 mg Tablets
- Enalapril 5mg Tablets
- Viskaldix Tablets
- Aricept Tablets
- Difflam Cream
- Alfentanil 500 micrograms/ml solution for injection
- Revlimid
- Benadryl Plus Capsules
- Diclomax Retard
- Voltarol Tablets
- Virgan
- DIXARIT (menopausal disorders)
- Rapiscan (regadenoson)
- Neurontin Capsules and Tablets
- Aprovel Film-Coated Tablets (sanofi-aventis Bristol-Myers Squibb SNC)
- Foradil
- Nystatin-Dome Suspension 100,000 I.U./ml
- Meningitec in pre-filled syringe
- Catapres Tablets 100mcg
- Kemadrin 5 mg Tablets
- SECTRAL 400mg tablets
- Sectral 100mg and 200mg
- Eucardic 25mg Tablets
- ALDOMET Tablets 250 mg
- Parvolex 200 mg/ml Concentrate for Solution for Infusion
- Mifegyne
- Pedea 5 mg/ml solution for injection
- Eucardic 12.5mg Tablets
- Qvar 100 Easi-Breathe
- Qvar 50 Easi-Breathe
- Eucardic 6.25mg Tablets
- Qvar MDI 50 micrograms
- Sonata 5 mg hard capsules
- PRO-EPANUTIN
- Xarelto 20mg film-coated tablets
Cholesterol
Tools for Effective CVD Management
ENTER
the Cholesterol Knowledge Centre
Please note that the Cholesterol Knowledge
Centre is intended for healthcare professionals only
Diagnosing and managing coronary heart disease (CHD) can be challenging. In most patients, it takes years or even decades before the underlying coronary pathology leads to clinical manifestations. Major emphasis is needed in controlling overall cardiovascular risk factors in CHD as risk factor control remains poor in these patients and increases the risk of an event.1
The Cholesterol Knowledge Centre offers you a range of tools that will help you identify, diagnose and decide upon an appropriate treatment strategy for your patients at risk of CHD. The Centre's educational aids will allow you to keep up to date with the latest research, recommendations and guidelines. It also offers you tools to help you keep your patients engaged in their therapy, thereby significantly reducing their risk of future cardiovascular events.
References:
1. Graham I et al. Eur J Cardiovasc Prev Rehab 2007; 14: E1-E40.
- LIPITOR
... inadequate. Lipitor also raises HDL-cholesterol and lowers the LDL/HDL and total cholesterol/HDL ratios. Lipitor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol, and apolipoprotein B in patients with homozygous familial ... - LESCOL XL (statin)
... an adjunct to diet for the reduction of elevated total cholesterol (total-C), low- density lipoprotein cholesterol ( LDL-C ), apolipoprotein B (apo B) and triglycerides (TG) levels and for the increase of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolaemia and ... - CHOLESTAGEL Film-Coated Tablets
... reduction in LDL-cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total and LDL- cholesterol in patients with isolated ... - Olbetam Capsules 250
Olbetam is indicated for the treatment of lipid disorders characterised, according to Fredrickson, by elevated plasma levels of triglycerides (type IV hyperlipo-proteinaemia), or cholesterol (type IIA hyperlipoproteinaemia) and triglycerides and cholesterol (type IIB hyperlipoproteinaemia ... - LOPID
... by hypertriglyceridaemia and/or low HDL-cholesterol. Primary hypercholesterolaemia, particularly when a statin is considered inappropriate or is not tolerated. Primary prevention Reduction of cardiovascular morbidity in males with increased non-HDL cholesterol and at high risk for a first ... - LIPANTIL MICRO
... of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. - Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled ...
